Stocktoria
Spyre Therapeutics, Inc. SYRE
Spyre Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886,000 | $2.3M | $18.7M | $0 | $0 | $3.9M | $5.2M | $4.6M |
| R&D expense | — | — | — | $58.6M | $57.1M | $59.6M | $64.6M | $36.7M | $22.8M | $18.1M |
| Operating income | -$209.6M | -$208.6M | -$242.3M | -$84.8M | -$65.6M | -$81.5M | -$80.3M | -$45.5M | -$27.7M | -$21.9M |
| Income tax | -$15,000 | $51,000 | -$26,000 | -$136,000 | $141,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M | -$65.8M | -$80.9M | -$78.3M | -$44.3M | -$27.2M | -$21.7M |
| EPS (diluted) | — | — | $-49.12 | $-24.86 | $-25.02 | $-1.52 | — | — | — | — |
| Operating cash flow | -$169.3M | -$157.4M | -$99.9M | -$80.1M | -$53.7M | -$75.8M | -$65.7M | -$32.2M | -$24.6M | -$18.8M |
| Free cash flow | — | -$157.4M | -$99.9M | -$80.2M | -$54.3M | -$80.1M | -$67.2M | -$32.6M | -$25.2M | -$19.1M |
| Cash & equivalents | $85.7M | $89.4M | $188.9M | $34.9M | $15.1M | $90.1M | $19.3M | $22.5M | $12.8M | $47.7M |
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M | $161.6M | $83.2M | $77.7M | $56.1M | $67.1M |
| Total liabilities | $62.5M | $90.7M | $73.3M | $20.8M | $26.0M | $21.8M | $23.1M | $10.3M | $5.7M | $4.1M |
| Shareholders' equity | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M | $139.8M | $60.1M | $67.4M | $50.3M | $63.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | -100.0% | -62.0% | -87.6% | — | — | -100.0% | -25.3% | +12.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.